This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related outcomes and was safe for use across different levels of SBP without causing an increase in short-term (acute) kidney injury, dehydration, or amputations in patients.

This study evaluated the long-term effects of a moderate low-carbohydrate diet (LCD) on blood glucose control and liver function in patients with type 2 diabetes (T2D). The data showed that patients on a moderate LCD diet showed better blood glucose control and liver function over the long term than patients on a traditional diabetic diet (TDD).

This study compared the effectiveness and safety of teneligliptin (Tenelia) to placebo in patients with type 2 diabetes (T2D) that was inadequately controlled with triple oral antidiabetic drugs (OADs). The study showed that teneligliptin may be considered as a fourth add-on OAD treatment in these patients.

This study assessed the effects of canagliflozin (Invokana) therapy on body composition, glucose control, insulin resistance, and systemic (whole body) inflammation in patients with newly-diagnosed type 2 diabetes (T2D) compared to metformin (Glucophage). The data showed that canagliflozin therapy reduced visceral fat tissue, and improved blood glucose, insulin resistance, and systemic inflammation in these patients.

This study determined the effect of varying carbohydrate and saturated fat dietary contents on cardiovascular disease (CVD) risk factors during weight-loss maintenance. The authors concluded that restriction of carbohydrates provided improved insulin resistance on lipoprotein metabolism, without unwanted side effects on low-density lipoprotein (LDL) cholesterol or inflammation.

This study assessed the link between metformin (Glucophage) use in hospitalized and non-hospitalized patients with diabetes and different outcomes due to coronavirus disease 2019 (COVID-19). The study showed that metformin use was associated with a protective effect in COVID-19 outcomes in patients with type 2 diabetes (T2D).

This study evaluated the effect of whole grain consumption in glycaemic (blood sugar) control of patients with diabetes. The data showed that whole grain consumption was beneficial for the control of blood glucose levels in these patients.

This study evaluated the antibody response and side effects associated with COVID-19 vaccines administration in patients with type 1 (T1D) and type 2 diabetes (T2D), people without diabetes. The data showed similar immune responses in patients with and without diabetes after the second COVID-19 vaccine, regardless of glucose control.

This study compared the effectiveness of chiglitazar (Bilessglu) and sitagliptin (Januvia) on glycemic (blood glucose) variations, insulin resistance, and inflammation levels in patients with type 2 diabetes (T2D). The data showed that chiglitazar treatment was more effective at improving insulin resistance and inflammation compared with sitagliptin in these patients.

This study evaluated the effect of physical activity interventions on glycemic variability (GV; glucose levels variations) in patients with diabetes. The data showed that physical activity was associated with significantly reduced GV in these patients.